EUVIMEDObjevte EUVIMED
ÜbersichtsarbeitOpen access · CC BY 4.0

What’s New in Ocular Drug Delivery: Advances in Suprachoroidal Injection since 2023

Kevin Y Wu iD, Angel Gao, Michel Giunta, Simon D Tran iD

Pharmaceuticals · 2024-07-30 · 17 (8) · 1007

DOI: 10.3390/ph17081007 ↗

At a glance

Übersichtsarbeit in Pharmaceuticals, published online on 2024-07-30. Written by Kevin Y Wu and 3 co-authors. Institution: Department of Surgery, Division of Ophthalmology, University of Sherbrooke, Sherbrooke, QC J1G 2E8, Canada. Cited 24 times so far (Crossref); 173 references. The full text is freely available (open access, CC BY 4.0).

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Despite significant advancements in ocular drug delivery, challenges persist in treating posterior segment diseases like macular edema (ME) and age-related macular degeneration (AMD). Suprachoroidal (SC) injections are a promising new method for targeted drug delivery to the posterior segment of the eye, providing direct access to the choroid and retina while minimizing systemic exposure and side effects. This review examines the anatomical and physiological foundations of the SC space; evaluates delivery devices such as microcatheters, hypodermic needles, and microneedles; and discusses pharmacokinetic principles. Additionally, advancements in gene delivery through SC injections are explored, emphasizing their potential to transform ocular disease management. This review also highlights clinical applications in treating macular edema, diabetic macular edema, age-related macular degeneration, choroidal melanoma, and glaucoma. Overall, SC injections are emerging as a promising novel route for administering ophthalmic treatments, with high bioavailability, reduced systemic exposure, and favorable safety profiles. Key therapeutic agents such as triamcinolone acetonide, dexamethasone, AAV-based gene therapy, and axitinib have shown promise. The field of suprachoroidal injection is progressing rapidly, and this review article, while attempting to encapsulate most of the published preclinical and clinical studies, mainly focuses on those that are published within 2023 and 2024.

Subjects

Author keywords

choroidcost-benefit analysishumansinjectionsintraocularquality of liferetinal diseasestreatment outcomevisual acuity

Authors and institutions

  • Department of Surgery, Division of Ophthalmology, University of Sherbrooke, Sherbrooke, QC J1G 2E8, Canada.
  • Faculty of Medicine, Queen's University, Kingston, ON K7L 3N6, Canada.
  • Faculty of Dental Medicine and Oral Health Sciences, McGill University, Montreal, QC H3A 1G1, Canada.

ORCID profiles: Kevin Y Wu, Simon D Tran

Cite

APA

Wu, K. Y., Gao, A., Giunta, M., & Tran, S. D. (2024). What’s New in Ocular Drug Delivery: Advances in Suprachoroidal Injection since 2023. Pharmaceuticals, 17(8), 1007. https://doi.org/10.3390/ph17081007

Vancouver

Wu KY, Gao A, Giunta M, Tran SD. What’s New in Ocular Drug Delivery: Advances in Suprachoroidal Injection since 2023. Pharmaceuticals. 2024;17(8):1007. doi:10.3390/ph17081007

BibTeX
@article{Wu2024,
  author = {Wu, Kevin Y and Gao, Angel and Giunta, Michel and Tran, Simon D},
  title = {What’s New in Ocular Drug Delivery: Advances in Suprachoroidal Injection since 2023},
  journal = {Pharmaceuticals},
  year = {2024},
  volume = {17},
  number = {8},
  pages = {1007},
  doi = {10.3390/ph17081007}
}
Start for free →